Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Joly

Showing results (111-120 of 346) with videos related to

Pageof 35
Sort By:
BMC Cancer|December 13, 2022
Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trialMarie Lange, Bénédicte Clarisse, Alexandra Leconte, et al.
Bulletin Du Cancer|September 10, 2019
[Relapse surveillance of patients with testicular germ cell tumor]Emeline Orillard, Elodie Klajer, Elsa Kalbacher, et al.
Plos One|November 13, 2025
Remotely supervised online cognitive training to reduce cognitive difficulties following chemotherapy in patients treated for localized breast cancer: Protocol of the Cog-Stim2 multicenter randomized controlled trialMarie Bousquet, Marie Lange, Justine Lequesne, et al.
BMC Cancer|September 26, 2021
CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureElodie Coquan, Pierre-Emmanuel Brachet, Idlir Licaj, et al.
European Urology|August 19, 2008
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancerAntoine Italiano, Cécile Ortholan, Stéphane Oudard, et al.
BJU International|March 17, 2010
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre studyJean-Christophe Eymard, Stéphane Oudard, Gwenaelle Gravis, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
La Revue Du Praticien|February 17, 2012
[Management of adverse effects of targeted therapy toxicities in oncology]Elodie Coquan, Patrick Henri, Sixtine de Raucourt, et al.
Bulletin Du Cancer|January 31, 2026
[French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of advanced cervical cancer]Renaud Sabatier, Christophe Hennequin, Jérôme Martin-Babau, et al.
Bulletin Du Cancer|June 23, 2022
[Metastatic renal cell carcinoma: Management of toxicities of combinations]Florence Joly, Jean-Marie Michot, Louis Marie Dourthe, et al.
Pageof 35

Showing results (111-120 of 346) with videos related to

Sort By:
Pageof 35
BMC Cancer|December 13, 2022
Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trialMarie Lange, Bénédicte Clarisse, Alexandra Leconte, et al.
Bulletin Du Cancer|September 10, 2019
[Relapse surveillance of patients with testicular germ cell tumor]Emeline Orillard, Elodie Klajer, Elsa Kalbacher, et al.
Plos One|November 13, 2025
Remotely supervised online cognitive training to reduce cognitive difficulties following chemotherapy in patients treated for localized breast cancer: Protocol of the Cog-Stim2 multicenter randomized controlled trialMarie Bousquet, Marie Lange, Justine Lequesne, et al.
BMC Cancer|September 26, 2021
CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failureElodie Coquan, Pierre-Emmanuel Brachet, Idlir Licaj, et al.
European Urology|August 19, 2008
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancerAntoine Italiano, Cécile Ortholan, Stéphane Oudard, et al.
BJU International|March 17, 2010
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre studyJean-Christophe Eymard, Stéphane Oudard, Gwenaelle Gravis, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
La Revue Du Praticien|February 17, 2012
[Management of adverse effects of targeted therapy toxicities in oncology]Elodie Coquan, Patrick Henri, Sixtine de Raucourt, et al.
Bulletin Du Cancer|January 31, 2026
[French recommendations for clinical practice, Nice-Saint-Paul de Vence 2024-2025: Management of advanced cervical cancer]Renaud Sabatier, Christophe Hennequin, Jérôme Martin-Babau, et al.
Bulletin Du Cancer|June 23, 2022
[Metastatic renal cell carcinoma: Management of toxicities of combinations]Florence Joly, Jean-Marie Michot, Louis Marie Dourthe, et al.
Pageof 35